Hoon-Chul Kang

Dr. Hoon-Chul Kang


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in Epilepsia
Verified
Journal Article
Closed access
PDF file
JKJeong A Kim
Jeong A Kim
JYJung‐Rim Yoon
Jung‐Rim Yoon
ELEun Joo Lee
Eun Joo Lee
JLJoon Soo Lee
Joon Soo Lee
JKJeong Tae Kim
Jeong Tae Kim
HKHoon-Chul Kang
Hoon-Chul Kang

3 August 2019 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
NSNam Suk Sim
Nam Suk Sim
AKAra Ko
Ara Ko
WKWoo Kyeong Kim
Woo Kyeong Kim
SKSe Hoon Kim
Se Hoon Kim
JKJu Seong Kim
Ju Seong Kim
JLJeong Ho Lee
Jeong Ho Lee

11 July 2018 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
YJYoonhee Jin
Yoonhee Jin
JLJung Seung Lee
Jung Seung Lee
JKJin Kim
Jin Kim
SMSungjin Min
Sungjin Min
SWSoohyun Wi
Soohyun Wi
SCSeung-Woo Cho
Seung-Woo Cho

1 January 2012 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
JJJiho Jang
Jiho Jang
JYJeong-Eun Yoo
Jeong-Eun Yoo
JLJeong-Ah Lee
Jeong-Ah Lee
DLDongjin R. Lee
Dongjin R. Lee
JKJi Young Kim
Ji Young Kim
DKDong-Wook Kim
Dong-Wook Kim
The generation of disease-specific induced pluripotent stem cell (iPSC) lines from patients with incurable diseases is a promising approach for studying disease mechanisms and drug screening. Such innovation enables to obtain autologous cell sources in regenerative medicine. Herein, we report the generation and characterization of iPSCs from fibroblasts of patients with sporadic or familial diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), juvenile-onset, type I diabetes mellitus (JDM), and Duchenne type muscular dystrophy (DMD), as well as from normal human fibroblasts (WT). As an example to modeling disease using disease-specific iPSCs, we also discuss the previously established childhood cerebral adrenoleukodystrophy (CCALD)- and adrenomyeloneuropathy (AMN)-iPSCs by our group. Through DNA fingerprinting analysis, the origins of generated disease-specific iPSC lines were identified. Each iPSC line exhibited an intense alkaline phosphatase activity, expression of pluripotent markers, and the potential to differentiate into all three embryonic germ layers: the ectoderm, endoderm, and mesoderm. Expression of endogenous pluripotent markers and downregulation of retrovirus-delivered transgenes [OCT4 (POU5F1), SOX2, KLF4, and c-MYC] were observed in the generated iPSCs. Collectively, our results demonstrated that disease-specific iPSC lines characteristically resembled hESC lines. Furthermore, we were able to differentiate PD-iPSCs, one of the disease-specific-iPSC lines we generated, into dopaminergic (DA) neurons, the cell type mostly affected by PD. These PD-specific DA neurons along with other examples of cell models derived from disease-specific iPSCs would provide a powerful platform for examining the pathophysiology of relevant diseases at the cellular and molecular levels and for developing new drugs and therapeutic regimens.

1 March 2018 in Epilepsy Research
Verified
Journal Article
Closed access
AKAra Ko
Ara Ko
SYSong Ee Youn
Song Ee Youn
SKSe Hee Kim
Se Hee Kim
JLJoon Soo Lee
Joon Soo Lee
SKSangwoo Kim
Sangwoo Kim
HKHoon-Chul Kang
Hoon-Chul Kang

1 February 2015 in Epilepsy Research
Verified
Journal Article
Closed access
HKHyo Jeong Kim
Hyo Jeong Kim
SKSe Hee Kim
Se Hee Kim
JLJoon Soo Lee
Joon Soo Lee
KHKyoung Heo
Kyoung Heo
DKDong-Seok Kim
Dong-Seok Kim
HKHoon-Chul Kang
Hoon-Chul Kang